Sarepta: TD Cowen downgrades rating, cuts PT on FDA pullback risk for Elevidys

TD Cowen downgraded Sarepta Therapeutics (SRPT) to "Hold" from "Buy", slashing the price target to $24 from $62, citing increased risk of FDA withdrawal of Elevidys approval following safety concerns and a second patient death due to acute liver failure. Analysts believe the FDA may reconsider both the accelerated approval for non-ambulatory patients and potentially the full approval for ambulatory patients, especially if Sarepta loses support from the DMD community due to concerns over undisclosed safety risks, including elevated liver function tests in approximately 30% of patients.

Analysis

Sarepta Therapeutics (NASDAQ:SRPT) faces significant headwinds following a downgrade by TD Cowen to "Hold" from "Buy," accompanied by a substantial price target reduction to $24 from $62. This revision is primarily driven by escalating safety concerns surrounding its gene therapy drug, Elevidys, notably after a second non-ambulatory patient died from acute liver failure post-treatment. TD Cowen analysts highlight a growing risk that the U.S. Food and Drug Administration (FDA) could withdraw Elevidys' accelerated approval for non-ambulatory patients and potentially reconsider its full approval for ambulatory patients. This risk is amplified by the potential loss of support from the Duchenne muscular dystrophy (DMD) patient community, stemming from concerns that Sarepta may not have adequately disclosed real-world safety risks, including reports that approximately 30% of patients experienced elevated liver function tests. The new $24 price target reflects a discounted cash flow model that now factors in the possibility of a complete market withdrawal of Elevidys. The reported sentiment score of -0.85 (extremely negative) and a market impact score of 0.75 further underscore the serious nature of these developments for SRPT's outlook.

Key Decisions for Investors

• Investors should exercise extreme caution with Sarepta Therapeutics, given the severe safety concerns surrounding Elevidys and the potential for FDA withdrawal of its approval.
• Closely monitor any forthcoming communications from the FDA regarding Elevidys, further safety data releases from the company, and sentiment shifts within the Duchenne muscular dystrophy patient community.
• Re-evaluate positions in SRPT considering the significantly increased risk profile, as the stock now faces a binary outcome heavily dependent on regulatory decisions and the drug's future viability.